Carbios reports reduced operating expenses and strong cash position for FY2025
Biorecycling technology firm Carbios announced its fiscal year 2025 financial results, highlighting a significant reduction in operating expenses. The company reported a solid cash position sufficient to cover expenditures beyond the next 12 months.
Clermont-Ferrand, France – Biotech firm Carbios released its fiscal year 2025 financial results on April 17, 2026, detailing operational and financial performance. The company reported a significant reduction in operating expenses, leading to a €7 million decrease in its operating loss.
As of December 31, 2025, Carbios maintained a consolidated cash position of €59 million. This provides the company with sufficient liquidity to cover its operating expenses for more than the coming 12 months. Projected cash consumption for 2026, excluding the Longlaville project, is estimated at €20 million.
For 2026, Carbios has outlined four strategic priorities: resuming the Longlaville industrial project pending financing completion (expected Q3 2026), deploying its PET biorecycling technology in Asia through a licensed facility with Wankai, accelerating commercial development for new license agreements in Europe, North America, and South America, and maintaining strict financial discipline.
Operating revenues for 2025 reached €5.7 million, up from €5.1 million in 2024, primarily from operating grants and services invoiced to its subsidiaries. Operating expenses decreased to €30.7 million from €37.5 million in 2024, attributed to cost-saving measures, headcount reductions, and lower external spending.